SP-002 not checked
Stamford Pharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration”In the company’s words, NCT06344052 on ClinicalTrials.gov
- Tested for
- Basal Cell Carcinoma
- Main trialPhase 2
- “The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will…”In the company’s words, NCT06344052 on ClinicalTrials.gov
Other drugs for Basal Cell Carcinoma
- BO-112Highlight Therapeutics · Phase 2
- STAR0602Marengo Therapeutics, Inc. · Phase 1/2
- MDNA11Medicenna Therapeutics, Inc. · Phase 1/2
- PembrolizumabMerck & Co. · Phase 1/2
- Vusolimogene OderparepvecReplimune, Inc. · Phase 1/2
- CemiplimabRegeneron · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Sep 2026 | To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026